Telik Will Continue Developing Telcyta Despite Three Phase III Failures
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says an independent review shows its ASSIST-3 trial may have been compromised by inappropriately dropped patients.
You may also be interested in...
FDA Puts Clinical Hold On Telcyta Following ASCO Presentation
Telik plans to submit additional safety and other information to FDA and request a meeting with the agency “as soon as possible.”
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.